loading
Precedente Chiudi:
$3.99
Aprire:
$3.81
Volume 24 ore:
5,116
Relative Volume:
0.27
Capitalizzazione di mercato:
$6.15M
Reddito:
$2.54M
Utile/perdita netta:
$-4.13M
Rapporto P/E:
-1.3495
EPS:
-2.89
Flusso di cassa netto:
$-4.11M
1 W Prestazione:
+6.56%
1M Prestazione:
+3.59%
6M Prestazione:
+4.84%
1 anno Prestazione:
+21.36%
Intervallo 1D:
Value
$3.81
$4.02
Intervallo di 1 settimana:
Value
$3.58
$4.08
Portata 52W:
Value
$2.78
$5.20

Xenetic Biosciences Inc Stock (XBIO) Company Profile

Name
Nome
Xenetic Biosciences Inc
Name
Telefono
781-778-7720
Name
Indirizzo
945 CONCORD ST., FRAMINGHAM, MA
Name
Dipendente
4
Name
Cinguettio
@XeneticBio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
XBIO's Discussions on Twitter

Confronta XBIO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
XBIO 4.0126 6.15M 2.54M -4.13M -4.11M -2.89
VRTX 449.15 115.43B 10.63B -479.80M -1.35B 13.33
REGN 745.69 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 599.62 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.88 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.45 24.89B 3.30B -501.07M 1.03B 11.54

Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-01-08 Iniziato Maxim Group Buy

Xenetic Biosciences Inc Borsa (XBIO) Ultime notizie

pulisher
09:13 AM

Xenetic presents preclinical data on DNase I with CAR T cells in murine model - TipRanks

09:13 AM
pulisher
08:32 AM

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - AccessWire

08:32 AM
pulisher
08:30 AM

Xenetic Bio's DNase I + CAR T Cell Therapy Shows Breakthrough in Melanoma Treatment | XBIO Stock News - StockTitan

08:30 AM
pulisher
Nov 15, 2024

Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 15, 2024
pulisher
Nov 13, 2024

Xenetic reports Q3 EPS (28c) vs. (69c) last year - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - AccessWire

Nov 13, 2024
pulisher
Nov 13, 2024

Xenetic Bio Q3: R&D Costs Drop 64% as DNase Cancer Program Advances | $6.8M Cash | XBIO Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Xenetic Biosciences: Q3 Earnings Snapshot - Houston Chronicle

Nov 13, 2024
pulisher
Nov 12, 2024

Xenetic presents preclinical data on DNase platform technology - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Oil City Derrick

Nov 12, 2024
pulisher
Nov 12, 2024

Xenetic's DNase I Breakthrough Boosts Cancer Immunotherapy Efficacy in Preclinical Study | XBIO Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 09, 2024

Xenetic Biosciences Extends Research Collaboration with The Scripps Research Institute - Defense World

Nov 09, 2024
pulisher
Nov 07, 2024

Xenetic extends research collaboration with Scripps Research Institute - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

Xenetic Biosciences Expands Collaboration for Cancer Treatment - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - AccessWire

Nov 07, 2024
pulisher
Oct 31, 2024

Xenetic Biosciences announces board member changes - Investing.com India

Oct 31, 2024
pulisher
Oct 31, 2024

Xenetic Biosciences announces board member changes By Investing.com - Investing.com UK

Oct 31, 2024
pulisher
Oct 26, 2024

Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Grows By 460.0% - Defense World

Oct 26, 2024
pulisher
Oct 22, 2024

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - AccessWire

Oct 22, 2024
pulisher
Oct 21, 2024

SEC Form S-3 filed by Xenetic Biosciences Inc. - Quantisnow

Oct 21, 2024
pulisher
Oct 17, 2024

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform - AccessWire

Oct 17, 2024
pulisher
Oct 16, 2024

Secondary Progressive Multiple Sclerosis Drug Market to Expand with Significant CAGR by 2034 |AB Science SA, Actelion Lt – IndiaPolitics.com - IndiaPolitics.com

Oct 16, 2024
pulisher
Oct 13, 2024

Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 50.0% - Defense World

Oct 13, 2024
pulisher
Sep 13, 2024

Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Decline in Short Interest - Defense World

Sep 13, 2024
pulisher
Sep 11, 2024

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - Kansas City Star

Sep 11, 2024
pulisher
Aug 22, 2024

Q3 2024 Earnings Estimate for Xenetic Biosciences Inc (NASDAQ:XBIO) Issued By HC Wainwright - Defense World

Aug 22, 2024
pulisher
Aug 21, 2024

XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024 - MSN

Aug 21, 2024
pulisher
Aug 21, 2024

Xenetic Biosciences (NASDAQ:XBIOW) Stock Price Up 33.9% - Defense World

Aug 21, 2024
pulisher
Aug 20, 2024

Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates - MSN

Aug 20, 2024
pulisher
Aug 20, 2024

Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright - Defense World

Aug 20, 2024
pulisher
Aug 18, 2024

Xenetic Biosciences Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line - Simply Wall St

Aug 18, 2024
pulisher
Aug 16, 2024

Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results, Hits Estimates - Defense World

Aug 16, 2024
pulisher
Aug 14, 2024

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - Markets Insider

Aug 14, 2024
pulisher
Aug 14, 2024

Xenetic Biosciences: Q2 Earnings Snapshot - CTPost

Aug 14, 2024
pulisher
Aug 13, 2024

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 3,550.0% in July - Defense World

Aug 13, 2024

Xenetic Biosciences Inc Azioni (XBIO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):